Yinglei Miao

机构：Nanjing Medical University · ORCID：0000-0003-4338-9338

发表论文 40 篇 · 总被引 720 次 · h-index 11

代表论文

• Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition) (2021 · Gut · 被引 189)
• Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study (2024 · The Lancet · 被引 107)
• Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies (2024 · The Lancet · 被引 95)
• Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross‐sectional study (2022 · Helicobacter · 被引 37)
• Multi-cohort analysis reveals colorectal cancer tumor location-associated fecal microbiota and their clinical impact (2025 · Cell Host & Microbe · 被引 33)
• STMN1 as a novel prognostic biomarker in HCC correlating with immune infiltrates and methylation (2022 · World Journal of Surgical Oncology · 被引 33)